New agents in chronic myelogenous leukemia

Jorge Cortes, Francis Giles

Research output: Contribution to journalArticlepeer-review


Multiple new agents are currently being developed in chronic myelogenous leukemia (CML). Most of these agents are now being investigated in patients who have developed resistance to imatinib. Their mechanisms of action are diverse and many may be synergistic with imatinib. These agents will be used soon in different combinations, most likely including imatinib, with the hope of obtaining a complete blockade of the intracellular pathways that are triggered by Bcr-Abl. If this is successful, complete eradication of disease may become a reality for the majority of patients with CML.

Original languageEnglish (US)
Pages (from-to)501-512
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number4
StatePublished - Nov 1 2003
Externally publishedYes


  • Bcr-abl
  • Chemotherapy
  • Chronic myelogenous leukemia
  • Imatinib
  • Intracellular pathways
  • New agents

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New agents in chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this